Overview

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Status:
Terminated

Trial end date:
2019-09-24

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies the side effects and best dose of ruxolitinib and to see how well it works in participants with chronic myeloid leukemia with minimal residual disease while on therapy with tyrosine kinase inhibitors. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Incyte Corporation
National Cancer Institute (NCI)

Treatments:

Dasatinib
Imatinib Mesylate
Janus Kinase Inhibitors